Royalty Pharma plc
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 Trading Arrangements
The following table describes the written plans for the sale of our Class A ordinary shares adopted orterminated by our executive officers and directors during the fourth quarter of 2023, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”).
| Name and Title | Action | Adoption/ Termination Date | Scheduled Expiration Date of Trading Plan (1) | Maximum Shares Subject to Trading Plan |
|---|---|---|---|---|
| Terrance Coyne Executive Vice President & Chief Financial Officer | Adoption | November 22, 2023 | October 17, 2024 | 480,000 |
| Marshall UristExecutive Vice President, Research and Investments | Adoption | December 20, 2023 | December 30, 2024 | 46,667 |
(1)A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.